3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
59
Colorectal Neoplasms
45
Rectal Neoplasms
35
Stomach Neoplasms
27
Pancreatic Neoplasms
27
Neoplasm Metastasis
24
Neoplasms
19
Colonic Neoplasms
18
Triple Negative Breast Neoplasms
7
Esophageal Neoplasms
6
Adenocarcinoma
6
Liver Neoplasms
5
Brain Neoplasms
5
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms, Unknown Primary
2
Melanoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Squamous Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Interventions
Docetaxel
3
nimotuzumab
1
WW Domain-Containing Oxidoreductase
1
Vinorelbine
1
Paclitaxel
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Carboplatin
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Advanced Non-Small Cell Lung Cancer
×
Capecitabine
×
Clear all
NCT00345059
2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3
Terminated
84 enrolled